Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17904632 | GLYCOSYLTRANSFERASES, POLYNUCLEOTIDES ENCODING THESE AND METHODS OF USE | May 2024 | February 2026 | Abandon | 42 | 0 | 1 | No | No |
| 18582845 | GENE BHLH35 FOR PROMOTING ANTHOCYANIN ACCUMULATION OF PLANTS AND APPLICATION THEREOF | February 2024 | February 2026 | Allow | 23 | 2 | 0 | Yes | No |
| 18486766 | METHOD FOR TERRESTRIAL CARBON SEQUESTRATION | October 2023 | June 2025 | Abandon | 20 | 0 | 1 | No | No |
| 18282642 | AGENT FOR INCREASING EXPRESSION OF GENE AND PHOTOSYNTHESIS ACTIVATING AGENT | September 2023 | November 2025 | Abandon | 26 | 0 | 1 | No | No |
| 18458027 | USE OF MULTIGENE STACKING METHOD IN SYNTHESIS OF NERVONIC ACID IN BRASSICA NAPUS | August 2023 | November 2025 | Abandon | 27 | 2 | 0 | No | No |
| 18309979 | USE OF RNA TO TREAT XYLELLA FASTIDIOSA INFECTION IN PLANTS | May 2023 | June 2025 | Abandon | 25 | 1 | 1 | No | No |
| 18309482 | TEA PLANT CsFAAH6 GENE AND USE THEREOF | April 2023 | December 2024 | Allow | 20 | 1 | 0 | Yes | No |
| 18032129 | ENGINEERING INCREASED SUBERIN LEVELS BY ALTERING GENE EXPRESSION PATTERNS IN A CELL-TYPE SPECIFIC MANNER | April 2023 | March 2026 | Allow | 35 | 1 | 1 | Yes | No |
| 18174103 | GENE-EDITING IN CANNABIS PLANT | February 2023 | March 2026 | Abandon | 37 | 1 | 1 | No | No |
| 18108996 | Plastid-transgene-encoded nuclear gene silencing | February 2023 | February 2026 | Abandon | 36 | 1 | 1 | No | No |
| 18154861 | METHOD AND BIOLOGICAL AGENT FOR CATALYZING ESTERIFICATION OF PLANT FREE CAROTENOIDS AND TRANSGENIC PLANT | January 2023 | June 2025 | Allow | 29 | 1 | 1 | Yes | No |
| 18004243 | SPOTTED WILT DISEASE RESISTANCE GENE RTSW FROM TOBACCO AND USE THEREOF | January 2023 | May 2025 | Allow | 28 | 1 | 0 | Yes | No |
| 18010819 | Powdery Mildew Resistant Grapevine Plant | December 2022 | January 2026 | Allow | 37 | 2 | 1 | Yes | No |
| 18009795 | GENE ENCODING CYTOCHROME P450 AND USE THEREOF | December 2022 | January 2026 | Allow | 37 | 1 | 1 | Yes | No |
| 17907040 | GENOME EDITING IN SUNFLOWER | September 2022 | May 2025 | Abandon | 31 | 0 | 2 | No | No |
| 17905591 | NUCLEIC ACID MOLECULES, POLYPEPTIDES HAVING EPOXY GROUP-REMOVING CATALYTIC ACTIVITY AND USE THEREOF | September 2022 | January 2026 | Allow | 41 | 2 | 1 | Yes | No |
| 17896596 | Method For Organically Planting Dendrobium | August 2022 | April 2025 | Allow | 31 | 1 | 0 | Yes | No |
| 17774705 | Cinnamomum Burmannii Monoterpene Synthase CBTPS1, Related Biomaterial Thereof And Application Thereof | May 2022 | March 2026 | Allow | 46 | 3 | 1 | Yes | No |
| 17634694 | ALTERATION OF FLAVOR TRAITS IN CONSUMER CROPS VIA DISABLEMENT OF THE MYROSINASE/GLUCOSINOLATE SYSTEM | February 2022 | July 2025 | Allow | 41 | 2 | 2 | Yes | No |
| 17609723 | SELF-COMPATIBILITY IN CULTIVATED POTATO | November 2021 | February 2026 | Allow | 51 | 2 | 2 | Yes | No |
| 16967390 | METHOD OF PRODUCING TRANSFORMED PLANT CELLS, CONTAINING RECOMBINANT HUMAN ALKALINE PHOSPHATASE, AND THE USE OF SAID TRANSFORMED PLANT CELLS, CONTAINING RECOMBINANT HUMAN ALKALINE PHOSPHATASE | August 2020 | December 2025 | Abandon | 60 | 2 | 1 | No | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner SPEED, DEQUANTARIUS JAVON works in Art Unit 1663 and has examined 2 patent applications in our dataset. With an allowance rate of 50.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 10000 months.
Examiner SPEED, DEQUANTARIUS JAVON's allowance rate of 50.0% places them in the 12% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by SPEED, DEQUANTARIUS JAVON receive 2.00 office actions before reaching final disposition. This places the examiner in the 50% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by SPEED, DEQUANTARIUS JAVON is 10000 months. This places the examiner in the 0% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +100.0% benefit to allowance rate for applications examined by SPEED, DEQUANTARIUS JAVON. This interview benefit is in the 100% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
This examiner enters after-final amendments leading to allowance in 50.0% of cases where such amendments are filed. This entry rate is in the 74% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 3% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.